Abstract:ID 92155 Poster Board 478 The Glucagon-like peptide 1 receptor (GLP-1R) belongs to the Class B G-protein coupled receptors (GPCRs) and is a well-established target for treating type 2 diabetes. Recent clinical-trial data suggest that GLP-1R agonistic drugs not only significantly reduce body weight in individuals with obesity, but may also offer protection against serious heart disease and drug/alcohol addiction related issues. Consequently, GLP-1R has become one of the most intriguing and extensively studied Class B GPCRs. Although GLP-1R agonist-based therapies, including various GLP-1 analog drugs, are highly successful and available in the market, most are peptidic in nature and require intravenous ( iv ) mode of administration. Thus, it remains a challenge to develop nonpeptidic agonist drugs targeting GLP-1R. A promising approach, involves the development of small molecule positive allosteric modulators (PAMs) of GLP-1R, which have a greater potential for more convenient oral ( po ) administration. Building upon our prior work that identified two 2-aminothiophene-based small-molecule PAMs of GLP-1R, we conducted a series of structural SAR optimizations, as well as in vitro and in vivo studies. This effort led to the identification of 2-aminothiophene derivative, I-187 (MW 299), which exhibited an approximately 2-fold increase in insulin secretion at 5 μM when combined with the GLP-1 peptide at 10 nM. I n vivo studies using CD1 mice revealed a 50% reduction in glucose levels after 60 minutes at a dose of 10 mg/kg b.w. More notably, co-treatment with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase IV, demonstrated that I-187 synergistically lowered blood glucose levels by approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. These promising results, coupled with the favorable drug-like properties of the compound, suggest that I-187 is a compelling lead compound for future drug development. Furthermore, this approach can potentially be applied to the development of allosteric modulation of other GPCRs. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM140406.

Discovery of Palindrome Dual PPARγ-GPR40 Agonists for Treating Type 2 Diabetes

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ

Scaffold-based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Rational design of thiazolidine-4-one-gallic acid hybrid derivatives as selective partial PPARγ modulators: an in-silico approach for type 2 diabetes treatment

Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications

Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation

A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties

Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and In vivo anti-diabetic evaluation

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptorγwith Excellent Effect on Insulin Resistance and Type 2 Diabetes

Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome

Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity

2-(3,4-Dihydro-2h-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a Novel, Synthetic Small Molecule That Alleviates Insulin Resistance and Lipid Abnormalities.

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes

Deciphering G-Protein-Coupled Receptor 119 Agonists As Promising Strategy Against Type 2 Diabetes Using Systems Biology Approach

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1h)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119.